Please assess the completion status of the following clinical trial:

Trial Title: Suicide Gene Therapy Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with primary immunodeficiencies, haematological malignancies or metabolic disorders at GOSH (children of both sexes, aged 0 to 16 years) undergoing haploidentical transplant~2. Both patient and donor must give informed consent in writing.~3. The donor must be willing, able and available for donation of T cells by collection of whole blood or leukapheresis.~4. The patient should be free of serious intercurrent illness.~Exclusion Criteria:~1. Donor unfit or unavailable~2. Donor positive for Hepatitis B or C, or HTLV-1, or HIV~3. Patient receiving Ganciclovir, Aciclovir, Cidofovir a result of active CMV, adenovirus, varicella zoster or herpes simplex infection infection~4. GVHD ≥ grade II before infusion of gene modified T cells~5. Serious intercurrent illness

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- HSVTK retrovirally-transduced donor T lymphocytes (Type: EXPERIMENTAL): HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).